PROM1 and vulva cancer: In contrast, in patients without recurrence, only 4/18 patients with vulvar cancer (grey dotted lines) showed an increase in PD-L1+ CD49f+ CD133+ CTC frequencies while 14/18 patients consistently showed decreasing frequencies.